REGENERON PHARMACEUTICALS, INC. Quarterly Research and Development Expense in USD from Q1 2010 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary: Regeneron Pharmaceuticals, Inc. quarterly/annual Research and Development Expense history and growth rate from Q1 2010 to Q3 2024.
Regeneron Pharmaceuticals, Inc. Research and Development Expense for the quarter ending September 30, 2024 was $1.27B, a 18.2% increase year-over-year.
Regeneron Pharmaceuticals, Inc. Research and Development Expense for the twelve months ending September 30, 2024 was $4.9B, a 13.8% increase year-over-year.
Regeneron Pharmaceuticals, Inc. annual Research and Development Expense for 2023 was $4.44B, a 23.6% increase from 2022.
Regeneron Pharmaceuticals, Inc. annual Research and Development Expense for 2022 was $3.59B, a 25.6% increase from 2021.
Regeneron Pharmaceuticals, Inc. annual Research and Development Expense for 2021 was $2.86B, a 8.05% increase from 2020.

Research and Development Expense, Trailing 12 Months (USD)

Research and Development Expense, Quarterly (USD)

Research and Development Expense, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024	$4.9B	$1.27B	+$196M	+18.2%	Jul 1, 2024	Sep 30, 2024	10-Q	2024-10-31
Q2 2024	$4.7B	$1.2B	+$115M	+10.6%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-01
Q1 2024	$4.59B	$1.25B	+$147M	+13.4%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-02
Q4 2023	$4.44B	$1.18B	+$134M	+12.9%	Oct 1, 2023	Dec 31, 2023	10-K	2024-02-05
Q3 2023	$4.3B	$1.08B	+$164M	+18%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-10-31
Q2 2023	$4.14B	$1.09B	+$291M	+36.6%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-01
Q1 2023	$3.85B	$1.1B	+$257M	+30.5%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-02
Q4 2022	$3.59B	$1.04B	+$306M	+41.4%	Oct 1, 2022	Dec 31, 2022	10-K	2024-02-05
Q3 2022	$3.29B	$911M	+$246M	+37%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-02
Q2 2022	$3.04B	$794M	+$80.1M	+11.2%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-03
Q1 2022	$2.96B	$844M	+$101M	+13.6%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-04
Q4 2021	$2.86B	$738M	+$81.1M	+12.4%	Oct 1, 2021	Dec 31, 2021	10-K	2024-02-05
Q3 2021	$2.78B	$665M	-$19.2M	-2.81%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-03
Q2 2021	$2.8B	$714M	-$7.8M	-1.08%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-03
Q1 2021	$2.81B	$743M	+$159M	+27.2%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-04
Q4 2020	$2.65B	$657M	+$104M	+18.8%	Oct 1, 2020	Dec 31, 2020	10-K	2023-02-06
Q3 2020	$2.54B	$685M	+$159M	+30.2%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-04
Q2 2020	$2.38B	$722M	-$164M	-18.5%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-05
Q1 2020	$2.55B	$584M	+$97.8M	+20.1%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-06
Q4 2019	$2.45B	$552M	+$669M		Oct 1, 2019	Dec 31, 2019	10-K	2022-02-07
Q3 2019	$1.78B	$526M	-$31M	-5.57%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-05
Q2 2019	$1.81B	$886M	+$356M	+67.3%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-05
Q1 2019	$1.46B	$486M	-$12.5M	-2.51%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-05
Q4 2018	$1.47B	-$116M	-$644M	-122%	Oct 1, 2018	Dec 31, 2018	10-K	2021-02-08
Q3 2018	$2.11B	$557M	+$27.3M	+5.14%	Jul 1, 2018	Sep 30, 2018	10-Q	2019-11-05
Q2 2018	$2.09B	$529M	+$19.3M	+3.79%	Apr 1, 2018	Jun 30, 2018	10-Q	2019-08-06
Q1 2018	$2.07B	$499M	-$8.84M	-1.74%	Jan 1, 2018	Mar 31, 2018	10-Q	2019-05-07
Q4 2017	$2.08B	$528M	+$48.7M	+10.2%	Oct 1, 2017	Dec 31, 2017	10-K	2020-02-07
Q3 2017	$2.03B	$530M	-$13.3M	-2.45%	Jul 1, 2017	Sep 30, 2017	10-Q	2018-11-06
Q2 2017	$2.04B	$510M	-$50M	-8.92%	Apr 1, 2017	Jun 30, 2017	10-Q	2018-08-02
Q1 2017	$2.09B	$507M	+$37.3M	+7.94%	Jan 1, 2017	Mar 31, 2017	10-Q	2018-05-03
Q4 2016	$2.05B	$479M	+$18M	+3.9%	Oct 1, 2016	Dec 31, 2016	10-K	2019-02-07
Q3 2016	$2.03B	$543M	+$117M	+27.5%	Jul 1, 2016	Sep 30, 2016	10-Q	2017-11-08
Q2 2016	$1.92B	$560M	+$170M	+43.5%	Apr 1, 2016	Jun 30, 2016	10-Q	2017-08-03
Q1 2016	$1.75B	$470M	+$127M	+37%	Jan 1, 2016	Mar 31, 2016	10-Q	2017-05-04
Q4 2015	$1.62B	$461M	+$109M	+31.1%	Oct 1, 2015	Dec 31, 2015	10-K	2018-02-08
Q3 2015	$1.51B	$426M	+$88.2M	+26.1%	Jul 1, 2015	Sep 30, 2015	10-Q	2016-11-04
Q2 2015	$1.42B	$390M	+$95.8M	+32.5%	Apr 1, 2015	Jun 30, 2015	10-Q	2016-08-04
Q1 2015	$1.33B	$343M	+$55.7M	+19.4%	Jan 1, 2015	Mar 31, 2015	10-Q	2016-05-05
Q4 2014	$1.27B	$352M	+$83.6M	+31.2%	Oct 1, 2014	Dec 31, 2014	10-K	2017-02-09
Q3 2014	$1.19B	$338M	+$114M	+50.7%	Jul 1, 2014	Sep 30, 2014	10-Q	2015-11-04
Q2 2014	$1.07B	$295M	+$107M	+57.1%	Apr 1, 2014	Jun 30, 2014	10-Q	2015-08-04
Q1 2014	$967M	$287M	+$107M	+59.4%	Jan 1, 2014	Mar 31, 2014	10-Q	2015-05-07
Q4 2013	$860M	$268M	+$87.1M	+48.1%	Oct 1, 2013	Dec 31, 2013	10-K	2016-02-11
Q3 2013	$773M	$224M	+$65.8M	+41.5%	Jul 1, 2013	Sep 30, 2013	10-Q	2014-11-04
Q2 2013	$707M	$187M	+$40.1M	+27.2%	Apr 1, 2013	Jun 30, 2013	10-Q	2014-08-05
Q1 2013	$667M	$180M	+$41.4M	+29.8%	Jan 1, 2013	Mar 31, 2013	10-Q	2014-05-08
Q4 2012	$626M	$181M	+$52M	+40.3%	Oct 1, 2012	Dec 31, 2012	10-K	2015-02-12
Q3 2012	$574M	$158M	+$30.4M	+23.7%	Jul 1, 2012	Sep 30, 2012	10-Q	2013-11-05
Q2 2012	$543M	$147M	+$4.22M	+2.95%	Apr 1, 2012	Jun 30, 2012	10-Q	2013-08-06
Q1 2012	$539M	$139M	+$9.47M	+7.32%	Jan 1, 2012	Mar 31, 2012	10-Q	2013-05-03
Q4 2011	$530M	$129M	+$3.83M	+3.06%	Oct 1, 2011	Dec 31, 2011	10-K	2014-02-13
Q3 2011	$526M	$128M	+$5.88M	+4.82%	Jul 1, 2011	Sep 30, 2011	10-Q	2012-10-24
Q2 2011	$520M	$143M	+$18.6M	+15%	Apr 1, 2011	Jun 30, 2011	10-Q	2012-07-25
Q1 2011	$501M	$129M	+$11.9M	+10.1%	Jan 1, 2011	Mar 31, 2011	10-Q	2012-04-26
Q4 2010	$489M	$125M			Oct 1, 2010	Dec 31, 2010	10-K	2013-02-15
Q3 2010		$122M			Jul 1, 2010	Sep 30, 2010	10-Q	2011-10-27
Q2 2010		$125M			Apr 1, 2010	Jun 30, 2010	10-Q	2011-07-28
Q1 2010		$117M			Jan 1, 2010	Mar 31, 2010	10-Q	2011-05-03

* An asterisk sign (*) next to the value indicates that the value is likely invalid.